ETH’s Paul Scherrer Institute has launched Araris Biotech to deliver production technology for site-specific ADCs that enable them to be used without being engineered from each patient.
Paul Scherrer Institute, part of the Domain of the Swiss Federal Institutes of Technology (ETH Domain) system, has unveiled Switzerland-based biotech company Araris Biotech to commercialise enhanced antibody-drug conjugates (ADCs).
Founded in January 2019, Araris Biotech is working on a technology for producing site-specific ADCs, antibodies chained to a biologically-active cytotoxic compound to treat diseases including cancer.
Site-specific ADCs generally offer better dosage tolerability for the patient than conventional ADCs, which are prone to adverse side-effects from the…
